{"id":"xelox-rt","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"XELOX (capecitabine + oxaliplatin) is a standard chemotherapy doublet where capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA, while oxaliplatin is a platinum agent that forms DNA crosslinks. When combined with radiotherapy (RT), the chemotherapy acts as a radiosensitizer to enhance tumor cell killing through multiple mechanisms of DNA damage.","oneSentence":"XELOX RT is a combination chemotherapy regimen with radiotherapy that uses capecitabine and oxaliplatin to inhibit DNA synthesis and repair while concurrent radiation damages tumor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:59.219Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced rectal cancer (neoadjuvant setting with radiotherapy)"}]},"trialDetails":[{"nctId":"NCT01643070","phase":"PHASE2","title":"Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Rectal Cancer, Liver Metastases","enrollment":38},{"nctId":"NCT06758830","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","status":"RECRUITING","sponsor":"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","startDate":"2025-01-07","conditions":"Rectal Cancer, Total Neoadjuvant Treatment, Neoadjuvant Therapy","enrollment":400},{"nctId":"NCT05000697","phase":"NA","title":"Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait","status":"RECRUITING","sponsor":"Hospital Alemão Oswaldo Cruz","startDate":"2021-07-14","conditions":"Rectal Cancer, Consolidation","enrollment":216},{"nctId":"NCT00093379","phase":"PHASE2","title":"Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-04","conditions":"Anal Cancer","enrollment":20},{"nctId":"NCT01490749","phase":"PHASE1","title":"Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-02","conditions":"Esophageal Cancer, Neoplasms, Esophageal","enrollment":17},{"nctId":"NCT03680261","phase":"PHASE3","title":"Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2018-10-01","conditions":"Gastric Cancer","enrollment":556},{"nctId":"NCT00268151","phase":"PHASE1","title":"Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"University of Louisville","startDate":"2005-02","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":24},{"nctId":"NCT01653301","phase":"PHASE3","title":"Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2005-10","conditions":"Rectal Cancer","enrollment":616},{"nctId":"NCT01064999","phase":"PHASE2, PHASE3","title":"A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2010-03","conditions":"Rectal Cancer","enrollment":240},{"nctId":"NCT00421824","phase":"PHASE2","title":"Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Rectal Neoplasms","enrollment":108},{"nctId":"NCT00557713","phase":"PHASE2","title":"XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma","status":"UNKNOWN","sponsor":"Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials","startDate":"2007-02","conditions":"Rectal Neoplasms, Locally Advanced Rectal Adenocarcinoma","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XELOX RT","genericName":"XELOX RT","companyName":"Catholic University of the Sacred Heart","companyId":"catholic-university-of-the-sacred-heart","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XELOX RT is a combination chemotherapy regimen with radiotherapy that uses capecitabine and oxaliplatin to inhibit DNA synthesis and repair while concurrent radiation damages tumor cells. Used for Locally advanced rectal cancer (neoadjuvant setting with radiotherapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}